Advancements in AAV-mediated Gene Therapy for Pompe Disease

Abstract excerpt

Pompe disease (glycogen storage disease type II) is caused by mutations in acid α-glucosidase (GAA) resulting in lysosomal pathology and impairment of the muscular and cardio-pulmonary systems. Enzyme replacement therapy (ERT), the only approved therapy for Pompe disease, improves muscle function by reducing glycogen accumulation but this approach entails several limitations including a short drug half-life and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Adenosine and Purinergic Signaling
• Share to Biochemical and Molecular Research
• Share to Lysosomal Storage Disorders Research